This study evaluates the effectiveness of oral dydrogesterone in preventing miscarriage in threatened abortion. Half of participants will receive oral dydrogesterone, while the other half will receive oral placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
100
Dydrogesterone tablet
Placebo tablet
Faculty of Medicine, Chulalongkorn University
Bangkok, Thailand
continue pregnancy more than 20 weeks gestation
percentage of cases with continue pregnancy more than 20 weeks gestation
Time frame: at 20 weeks gestation
preterm delivery less than 34 weeks
percentage of delivery less than 34 weeks
Time frame: at 34 weeks gestation
preterm delivery less than 37 weeks
percentage of delivery less than 37 weeks
Time frame: at 37 weeks gestation
placenta previa
percentage of placenta previa
Time frame: 31 weeks
abruptio placenta
percentage of abruptio placenta
Time frame: 31 weeks
Intrauterine growth restriction
percentage of intrauterine growth restriction
Time frame: 31 weeks
neonatal complications
percentage of newborn with respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, death
Time frame: 31 weeks
side effects
percentage of side effects such as headache, nausea/vomiting
Time frame: 6 weeks
compliance
percentage of complete drug use
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 6 weeks
maternal satisfaction
percentage of good satisfaction
Time frame: 6 weeks
time until bleeding stops
time from first bleeding until bleeding stops
Time frame: 6 weeks